PMID- 1726189
OWN - NLM
STAT- MEDLINE
DCOM- 19920630
LR  - 20220311
IS  - 0091-3057 (Print)
IS  - 0091-3057 (Linking)
VI  - 40
IP  - 4
DP  - 1991 Dec
TI  - Serotonin neurotoxicity in rats after combined treatment with a dopaminergic 
      agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) 
      analogue.
PG  - 915-22
AB  - There is increasing evidence linking dopamine (DA) to the long-term serotonergic 
      (5-HT) neurotoxic effects of certain substituted amphetamines such as 
      3,4-methylenedioxymethamphetamine (MDMA). The present study was undertaken to 
      examine the importance of DA metabolism, uptake inhibition and release in the 
      long-term effects of these drugs by combining various dopaminergic agents with an 
      analogue of MDMA that had low neurotoxic liability, namely 
      5,6-methylenedioxy-2-aminoindan (MDAI). Monoamine and metabolite levels and the 
      number of 5-HT uptake sites (using [3H]paroxetine binding) were determined 3 
      hours or 1 week after treatments. Combining the monoamine oxidase inhibitors, 
      clorgyline (MAOA selective) or deprenyl (MAOB selective) with MDAI did not result 
      in any long-term reductions of serotonergic markers. Similarly, combining the DA 
      uptake inhibitor GBR-12909 with MDAI did not result in any long-term changes in 
      monoamine levels at 1 week. In contrast, a single pretreatment of posttreatment 
      with the nonvesicular DA releaser S-amphetamine and MDAI resulted in small but 
      significant long-term changes in monoamine levels. More importantly, if a 
      subacute dosing regimen (every 12 hours for 4 days) was utilized, the combination 
      of S-amphetamine with MDAI resulted in a marked long-term decrease in the levels 
      of cortical, hippocampal and striatal 5-HT, 5-HIAA and the number of 5-HT uptake 
      sites. The results are discussed in terms of the significance of DA and 
      especially nonvesicular DA release in the long-term effects of MDMA-like drugs.
FAU - Johnson, M P
AU  - Johnson MP
AD  - Department of Pharmacology and Toxicology, School of Pharmacy and Pharmacal 
      Sciences, Purdue University, West Lafayette, IN 47907.
FAU - Huang, X M
AU  - Huang XM
FAU - Nichols, D E
AU  - Nichols DE
LA  - eng
GR  - DA-04758/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pharmacol Biochem Behav
JT  - Pharmacology, biochemistry, and behavior
JID - 0367050
RN  - 0 (Dopamine Agents)
RN  - 0 (Indans)
RN  - 0DMJ6G3XBF (5,6-methylenedioxy-2-aminoindane)
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - 333DO1RDJY (Serotonin)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 54-16-0 (Hydroxyindoleacetic Acid)
RN  - CK833KGX7E (Amphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
RN  - X77S6GMS36 (Homovanillic Acid)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/metabolism
MH  - 3,4-Methylenedioxyamphetamine/administration & dosage/analogs & 
      derivatives/toxicity
MH  - Amphetamine/administration & dosage/toxicity
MH  - Animals
MH  - Brain/*drug effects/metabolism
MH  - Dopamine/metabolism
MH  - Dopamine Agents/administration & dosage/*toxicity
MH  - Homovanillic Acid/metabolism
MH  - Hydroxyindoleacetic Acid/metabolism
MH  - Indans/administration & dosage/*toxicity
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Rats
MH  - Serotonin/*metabolism
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
AID - 0091-3057(91)90106-C [pii]
AID - 10.1016/0091-3057(91)90106-c [doi]
PST - ppublish
SO  - Pharmacol Biochem Behav. 1991 Dec;40(4):915-22. doi: 
      10.1016/0091-3057(91)90106-c.